Immune Modifying Nanoparticles Reduce Heart Attack Damage - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Immune Modifying Nanoparticles Reduce Heart Attack Damage


Cour Pharmaceutical Development Company, a biopharmaceutical company, has published new data showing that its proprietary nanoparticle therapy could potentially reduce inflammation and promote tissue repair and regeneration in patients who have had a heart attack.

In this study, published in Science Translational Medicine, animal models were injected with Immune Modifying Nanoparticles (IMP) following a heart attack. Scientists found that the size of the heart lesions was reduced by half and as a result, the heart could pump significantly more blood. IMP treatment demonstrated the ability to reduce inflammation and promote regeneration in all models tested.

"This is the first therapy that specifically targets a key driver of the inflammation that occurs after a heart attack," said Daniel Getts, chief scientific officer at Cour, in a press statement. "There is no other therapy on the horizon that can protect the heart from the aggressive immune cell infiltration that causes so much damage."

"IMP therapy represents a significant step toward the next generation of immune modulating agents," said John J. Puisis, CEO of Cour, in the same release. He added, "Our first priority as a company is to bring IMPs to patients who've suffered acute myocardial infarction, where we see a tremendous opportunity to improve clinical outcomes and quality of life."

The nanoparticles are proprietary compositions based on poly-lactic-co-glycolic acid, a biocompatible and biodegradable substance already approved by the FDA for use in a range of therapeutics. Efficacy has also been demonstrated in several other inflammatory models, such as West Nile virus, encephalitis, peritonitis, multiple sclerosis, and inflammatory bowel disease.

Source: Cour Pharmaceutical Development Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here